NSPR arrives at its May 4 earnings release in a deeply damaged technical state — the stock has shed 29% over the past month to close at $1.15, and the RSI has fallen to 26.8, well into oversold territory.
The price decline tells the dominant story heading into the print. NSPR is down 34% year-to-date, and the pace of selling accelerated over the past week with an 8% drop. That move has left the stock trading at a fraction of where analysts have been pitching it — the consensus target of $5.00 implies an analyst-derived upside of roughly 338%. That gap warrants a caveat: the consensus is stale (last updated February 2026), and the most recent analyst action on record is from Piper Sandler in May 2025, when the firm trimmed its target to $4.00 while keeping an Overweight rating. The directional message from the Street remains bullish, but the data is too dated to treat as a live signal.
Short interest is not the story here. At just 0.08% of the free float, there is effectively no meaningful short position in the stock. What is notable is the pace of recent change: estimated short shares rose 36% over the past week and 28% over the past month, though the absolute level remains trivial. Borrow conditions are loose — availability is ample and the cost to borrow runs near 4.8%, broadly unremarkable for a micro-cap. There is no squeeze dynamic, no borrow squeeze, and no elevated DTC pressure; the ORTEX short score of 29 reflects a low-conviction short community.
The options market paints a picture of near-total disengagement. The put/call ratio is running at 0.0024, below its already-thin 20-day mean of 0.0031, and the 52-week high on the PCR was just 0.33. This is an illiquid options market with minimal hedging activity — it does not convey meaningful directional information about how professional traders are positioned. The company's financials add context: estimated revenue of around $13.9 million against a normalized net loss of roughly $63 million and operating cash outflow near $40 million underscore that this remains a pre-profitability medical device name. Institutional holders — including OrbiMed Advisors and Aberdeen Group, which added shares through end of 2025 — hold concentrated positions, but the last reported changes were as of December 31.
The May 4 print will test whether InspireMD can show any revenue traction for its CGuard carotid stent system sufficient to slow the cash burn narrative that has weighed on the stock all year.
See the live data behind this article on ORTEX.
Open NSPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
